OST-tADC

OST-tADC refers to a proprietary tunable Antibody Drug Conjugate (tADC) platform developed by OS Therapies. This technology uses smaller targeting moieties or ligands, which allow for deeper tumor penetration and more effective delivery of cytotoxic agents directly to cancer cells. The tADCs selectively bind to specific receptors on cancer cells, are internalized via endocytosis, and then release their payloads—cell-penetrating agents (CAPs)—within the acidic environment of the tumor cell’s endosome or lysosome. The SiLinker technology ensures that the drug is only released in targeted areas with low pH, maximizing anti-tumor activity while minimizing toxicity to healthy tissue through a "bystander effect." OST-tADCs are chemically assembled for precise control over payload attachment and rapid clearance from the body, reducing systemic toxicity. The platform is being developed primarily for solid tumors such as ovarian cancer and other cancers expressing relevant targets[1][3][4][5].